Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors

Recruiting now · Not applicable

Conditions studied: Olanzapine, Breast Cancer, Dexamethasone

In brief

The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast cancer patients with metabolic risk factors.

Key facts

Study ID

NCT07743827

Run by

Alexandria University

People needed

90

Starts

2026-05-10

Expected to finish

2027-10-15

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients ≥18 years.
• Stage I-III breast cancer.
• Scheduled to receive AC chemotherapy.
• Presence of metabolic risk factors (diabetes, prediabetes, obesity, metabolic syndrome).
• ECOG performance status ≤2.

You may not qualify if…

• Recent systemic corticosteroid use.
• Active nausea or vomiting before chemotherapy.
• Severe renal or hepatic impairment.
• Uncontrolled diabetes or hypertension.
• Psychiatric illness affecting adherence.
• Pregnancy or lactation.
• Active infections or inflammatory diseases.
• Participation in another clinical trial

Where it is running

• Alexandria Main University Hospital — Alexandria, Alexandria Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.